Dr. Facente was a co-investigator on this two-year research study funded by the National Institute on Drug Abuse (NIDA), with the goal of better understanding the epidemiology of hepatitis C in three high-burden subpopulations in San Francisco.
Project Descriptions
Research Coordination and Data Analysis for an NIH R21 Study on Hepatitis C Epidemiology
Evaluating Naloxone Boxes to Prevent Overdoses in Michigan
Harm Reduction Michigan
National HIV Behavioral Surveillance (NHBS) Data Analysis
CDPH Office of AIDS
Collective Impact Backbone Support and Data Analysis to Eliminate Hepatitis C
End Hep C SF
Project Coordination and Analytic Support to Improve Global HIV Incidence Estimation
The Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA)
Evaluation for CDC-Funded Workforce Development for San Francisco Department of Public Health
SFDPH Center for Learning and Innovation
Evaluation for CDC-Funded Syringe Service Program Vaccine Scale-Up
NASTAD
Support for Viral Hepatitis Surveillance Planning, Data Analysis, and Reporting
San Francisco Department of Public Health ARCHES Branch
Formal Assessment of the Landscape of Medications for Addiction Treatment (MAT) in California
The Center at Sierra Health Foundation
Harm Reduction Readiness Assessment in Southeast San Diego
County of San Diego Public Health Services
Statistical Analysis to Support Evaluation of a LGBTQ+ Mental Health Intervention
LGBTQ Connection
Needs Assessment of Hepatitis C Testing and Treatment in the Jail System
End Hep C SF
Facente Consulting was selected by End Hep C SF to design and lead a mixed-methods needs assessment to identify gaps in hepatitis C (HCV) testing and treatment in San Francisco jails, identify best practices for treatment and linkage, and develop a HCV care cascade for people currently or recently incarcerated.
Assistance to Develop a System of Panel Management within a Jail Medical System
SFDPH Jail Health Services
Statistical Support for an Advanced HIV Prevention Clinical Trial Design
Gilead Sciences
Facente Consulting supported Gilead Sciences with statistical analysis relating to HIV incidence rates, assisting with the study design, analysis plan, and interpretation of study data for the PURPOSE trials–ultimately leading to the groundbreaking FDA approval of the twice-yearly PrEP medication Lenacapavir.